Anthem Biosciences sees 1.7 crore shares changing hands as Societe Generale, Prudential, among others, buy 3% stake

The transaction also drew participation from several domestic mutual funds, insurance companies, and an investment firm, according to block deal data on the National Stock Exchange (NSE).

These investors bought a total of 1.71 crore shares on Thursday, June 18, representing a 3.05% stake in Anthem Biosciences, at an average price of ₹744.80 apiece.

The aggregate transaction value stood at ₹1,274.69 crore.

Other foreign investors that participated in the deal were Luxembourg-based Nordea Asset Management, Integrated Core Strategies Asia Pte Ltd, and Social Protection Fund.

Among domestic institutional investors, the buyers included SBI Mutual Fund (MF), HDFC MF, Kotak Mahindra MF, UTI MF, Edelweiss MF, Canara Robeco MF, 360 ONE MF, Mahindra Manulife MF, and WhiteOak Capital MF.

PI Opportunities AIF V LLP, an affiliate of Premji Invest, Kotak Mahindra Life Insurance Company, Bajaj Life Insurance, and ICICI Prudential Life Insurance were also among the investors that acquired shares of the firm.

Meanwhile, promoter Aruna Ganesh sold an equal number of shares and exited the company.

Following the transaction, the combined holding of promoters and promoter group entities in Anthem Biosciences declined to 71.63% from 74.68%.

Anthem Biosciences is a fully integrated Contract Research, Development and Manufacturing Organisation.

Anthem Biosciences stock performance

Shares of Anthem Biosciences declined as much as 0.88% to hit an intraday low of ₹791.05 apiece during the noon session on the NSE on Friday. While the stock had opened in the red zone, it had surged as much as 2.09% to reach the session’s peak of ₹814.80 per equity share in early deals.

At around 12:24 PM, the scrip was trading 0.46% lower at ₹794.40 per equity share. The stock has gained nearly 1% over the month and 24% on a year-to-date basis.

While the share hit a 52-week high of ₹873.50 on September 19, 2025, it touched a year’s low of ₹579.15 per unit on February 2, 2026.

Anthem Biosciences has a total market capitalisation of ₹44,765.56 crore as of June 19, 2026, according to data on the NSE.